Investor Presentation

Company Overview XV Platform Product Pipeline The XV Technology platform provides for the rapid deployment of product for various indications. XV Lung Ventilation Analysis Software (LVAS) - FDA Clearance obtained & Australian TGA approved • The XV LVAS provides physicians a patient's regional measurements of ventilation at each phase of the breath - a key measurement offering physicians functional data on lung health at unprecedented levels of detail. • • FDA approved with wide indication for use provides for broad use by physicians Australian TGA approval for inclusion in the Australian Register of Therapeutics Goods allows for local commercial sales Ventilation Perfusion (VQ) - Clinical trials begin 2021 • VQ is a combination diagnostic, designed to compete with the Nuclear Medicine V/Q scan and measure both ventilation and perfusion. However, unlike the Nuclear Medicine V/Q scan, the XV Technology VQ report is completely contrast free. Ventilation is measured using the XV LVAS and perfusion is measured using a precursor to 4DMedical's CFPA technology. Contrast free Pulmonary Angiography (CFPA) - Clinical trials begin 2021 CFPA is a novel, non-invasive imaging technique that provides regional measurements of the pulmonary vasculature - the blood vessels which carry oxygen from the lungs to the heart - enabling the evaluation of lung health through the blood network. Expected Commercialisation Milestones ENGINEERING USA CLINICAL TRIALS USA ANZ APPROVAL USA ANZ COMMERCIALISATION USA ANZ Pg 18 Investor presentation |2020 2021 VQ CFPA XV XV XV 2022 2023 VQ CFPA VQ CFPA VQ CF VQ CF VQ CFPA XV 4DMedical™ FORMERLY 4D

View entire presentation